格隆汇1月2日丨迈博药业-B(02181.HK)公告，近日，公司核心产品之一，自主开发的重组抗肿瘤坏死因子α（“TNFα”）人鼠嵌合单克隆抗体CMAB008类停（注射用英夫利西单抗）的注册获巴基斯坦药品监管局批准，用于治疗：(i)成人溃疡性结肠炎；(ii)强直性脊柱炎；(iii)类风湿关节炎；(iv)成人及6岁以上儿童克罗恩病；(v)瘘管性克罗恩病；及(vi)银屑病。CMAB008类停?为首个获准...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.